Allogeneic hematopoietic cell transplantation (HCT) is the only treatment for selected inherited metabolic storage diseases (IMSD); a significant shortcoming is failure to achieve donor-derived engraftment. This study was undertaken to determine whether busulfan pharmacokinetics ( 
Hematopoietic cell transplantation (HCT) is an accepted treatment for lymphohematopoietic malignancies, bone marrow failure syndromes, and inherited metabolic storage diseases (IMSD). Experience with HCT for selected IMSD including Hurler syndrome, Maroteaux-Lamy syndrome, ␣-mannosidosis, and the leukodystrophies extends over two decades. [1] [2] [3] [4] [5] [6] Timely transplantation has cross-corrected the specific protein or lysosomal enzyme deficiency, halted the progression of somatic disease, stabilized neuropsychological function and permitted long-term survival; however, graft failure has been a significant obstacle to successful HCT. 7, 8 Numerous HCT conditioning regimens have been evaluated in patients with IMSD. While busulfan is contained in the majority of these regimens, little is known about its pharmacokinetics in children with IMSD. In other HCT populations, busulfan pharmacokinetics (BU PK) are agedependent and highly variable among individuals. 9, 10 Apparent clearance (Cl/F) of BU decreases substantially in the first decade of life. [11] [12] [13] Low BU levels in children are attributed to high clearance, although poor absorption and altered distribution may also play a role. Glutathione-Stransferase (GST) A1-1 is the major isoform involved in busulfan conjugation. 14 Recently, Gibbs et al 13 demonstrated that intestinal biopsy specimens from young children had significantly higher busulfan conjugation rates than those of older children. Hence, higher BU clearance in young children appears to be related to enhanced intestinal GST A1-1 expression. Lower exposure to BU has been associated with poorer rates of hematopoietic engraftment. 15 We reported that neither T lymphocyte depletion nor irradiation influenced the likelihood of engraftment following unrelated donor (URD) HCT for Hurler patients. 7 However, nucleated cell dose per kilogram of recipient body weight was statistically significant in affecting donorderived engraftment and survival. Other groups have recently reported on the role of nucleated cell, CD34
ϩ and CD3 ϩ doses in engraftment, GVHD, and survival in various transplant populations. [16] [17] [18] [19] [20] [21] [22] This study was undertaken to characterize BU PK in children with IMSD and to determine whether BU concentrations and hematopoietic cell doses are important in achieving donor-derived engraftment after allogeneic HCT.
Bone Marrow Transplantation

Patients and methods
Patients
BU PK were measured in 39 patients with IMSD undergoing HCT from December 1992 to July 1997 at University of Minnesota or collaborating institutions. Patient characteristics are described (Table 1) . Patients were not eligible for HCT if they had major hepatic, renal, cardiac or pulmonary dysfunction, or other potentially life-threatening problems. Patients undergoing a second HCT were not eligible for this study. The respective Institutional Review Boards approved the protocols. Consent was obtained from parents, guardians or patients.
Preparative regimen
Patients received a preparative regimen of BU/ cyclophosphamide (CY)/total body irradiation (TBI) consisting of BU 40 mg/m 2 p.o. given every 6 h for eight doses (total BU dose 320 mg/m 2 ), followed by CY 60 mg/kg i.v. once daily for 2 days (total dose 120 mg/kg), followed by TBI consisting of 750 cGy in one fraction. BU was given as 2 mg tablets (Glaxo Wellcome, Research Triangle Park, NC, USA) with doses to the nearest 1 mg. Children who were able to swallow pills were given BU tablets encased in gelatin capsules. If the child was very young or unable to swallow the tablet, it was crushed and administered by the nursing staff. All patients received phenytoin for seizure prophylaxis, beginning prior to BU administration.
Graft-versus-host disease (GVHD) prophylaxis
All patients received cyclosporine and prednisone for GVHD prophylaxis. Patients undergoing related (n ϭ 3) or unrelated donor (n ϭ 33) bone marrow HCT also received antithymocyte globulin and donor marrow T cell depletion by counterflow elutriation. 23 Three patients received unrelated donor umbilical cord blood transplants that were not Pharmacokinetic parameters were calculated using a onecompartment model. Area under the curve (AUC), mean BU plasma concentration (Cp) and oral clearance corrected for bioavailability (Cl/F) were calculated for both steadystate dosing pharmacokinetic sets. Cl/F was expressed in ml/min relative to body weight. AUC at steady state was calculated using the trapezoidal rule. The Cp was calculated from the ratio of AUC to the actual dosing interval for each patient. Cl/F was calculated by dividing dose by AUC over a single dosing interval. F was the fraction of the dose reaching the systemic circulation after oral administration.
Engraftment, veno-occlusive disease (VOD) and survival
Patients were studied at or near day 100 for early donorderived engraftment and у6 months for late engraftment.
Patients not surviving to day 21 were not evaluated. Engraftment was evaluated by peripheral blood or bone marrow restriction fragment length polymorphism (RFLP). Full, partial, and failed engraftment were defined as у90%, 11-89%, and р10% donor-derived cells by RFLP analysis, respectively, without additional stem cell infusions. VOD was diagnosed clinically in the presence of hyperbilirubinemia, ascites, and hepatomegaly. Survival was evaluated at 1 and 4 years.
Statistical analysis
Median and mean Ϯ standard deviation were calculated for the BU PK parameters obtained with the fourth and eighth doses. Statistical comparisons of the BU PK parameters across dose, age, and diagnosis were completed with the general Wilcoxon test. The correlation between dose four PK parameters and weight, body surface area and age was estimated by Spearman's correlation coefficient. Evaluation of engraftment among variables was performed with a Pearson's chi-square test or Fisher's exact test where appropriate. 25 The variables investigated were BU PK parameters, diagnosis, age, gender, weight, BU dose, donor type and marrow dose. Survival curves were calculated by the method of Kaplan and Meier. 26 Statistical comparisons were performed using SAS (SAS Institute, Cary, NC, USA). AUC ϭ area under the curve; C1/F ϭ average oral clearance corrected for bioavailability; Cp ϭ average BU plasma concentration. PK data expressed as median (range). 
Results
Pharmacokinetic analysis
Steady-state BU PK parameters obtained with the fourth and eighth doses are summarized (Table 2) . BU disposition showed wide inter-patient variability with up to 5.5-fold variation in initial Cl/F (ml/min/kg) estimates between lowest (2.1) and highest (11.4) values. Median BU PK parameters, Cl/F (ml/min/kg), AUC (ng min/ml) and Cp (ng/ml) were different between the two steady-state sampling periods (P р 0.05). Children Ͻ3 years of age had higher Cl/F ml/min/kg (P Ͻ 0.01) ( Table 3) . BU PK in children with Hurler syndrome were compared to children with other IMSD (Table  4) . Children with Hurler syndrome and other IMSD had a median age of 1.5 and 4.2 years, respectively (P Ͻ 0.01). There was a trend toward a lower Cp in children with Hurler syndrome (P ϭ 0.06). The correlation (r) between Cp and age was 0.48 (P ϭ Ͻ0.01). There was poor correlation between Cp and weight (P ϭ 0.07). Partial and failed engraftment occurred in two (7%) and six (22%), respectively. More children with other IMSD (10 of 13, 77%) achieved late full engraftment than those with Hurler syndrome (nine of 14, 64%) (P ϭ NS). Although, full and partial engraftment was not different in children with other IMSD (10 of 13, 77%) and Hurler syndrome (11 of 14, 78%) (P ϭ NS), all cases of partial engraftment occurred in children with Hurler syndrome. Children with late full engraftment had achieved a median BU Cp of 884 ng/ml (range, 314-1780) and those who failed to engraft achieved a Cp of 751 ng/ml (range, 510-969) (P ϭ NS).
Veno-occlusive disease and survival
Three of 39 (8%) patients developed VOD (Table 5) . No children with a Cp Ͻ1000 ng/ml developed VOD compared to three of 14 (21%) patients when the Cp exceeded 1000 ng/ml. All children who developed VOD died. Because of the small numbers of patients developing VOD, statistical analysis was not conducted.
Overall, 1 and 4 year survival was 67% and 56% in Hurler and other IMSD patients (P Ͼ 0.8).
Discussion
We report the largest evaluation of BU PK in children with IMSD, particularly Hurler syndrome, and examine the relationship between BU PK, hematopoietic cell, and donor-derived engraftment with a BU/CY/TBI regimen. While children р3 years of age had a significantly lower Cp and AUC and higher Cl/F, we found that BU PK did not differ in Hurler children compared to other IMSD patients. Furthermore, BU PK parameters in IMSD patients were comparable to those of children with malignant disease and marrow failure syndromes. We concluded that neither BU PK nor hematopoietic cell dose over the observed range accounts for donor-derived engraftment failure in both Hurler syndrome and children with other IMSD.
Inherited metabolic storage diseases represent a diverse group of lysosomal enzyme deficiency states. These enzymes are normally produced by the monocyte/ macrophage system and are responsible for degradation of cellular substrate. Systemic substrate accumulation causes neuropsychological decline, skeletal abnormalities, hepatosplenomegaly and cardiorespiratory embarrassment. Successful HCT with donor-derived engraftment replaces the defective monocyte/macrophage system and produces enzyme that clears accumulated substrate. Poor donor engraftment results in decreased or absent enzyme production, respectively, while full donor chimerism most effectively halts disease progression. Achieving full donor chimerism has been a major challenge in Hurler children following both related and unrelated donor HCT. This phenomenon remains unexplained. Busulfan pharmacokinetics have been extensively studied in children; however, data in children with IMSD have been limited. It has been hypothesized that BU PK differ in children with IMSD because they present to HCT without having received prior myelo-or immunosuppressive chemotherapy. Vassal et al 27 reported that children Ͻ3 years of age (n ϭ 6) with IMSD had higher oral mean BU CL/F compared to children Ͻ3 years of age with immunodeficiency disorders or leukemia (n ϭ 27) (mean 8.7 Ϯ 3.3 vs 6.3 Ϯ 2.8 ml/min/kg, P ϭ 0.07). These data suggested that children with IMSD had greater BU metabolic capacity and potentially at higher risk for poor donor-derived engraftment. Grochow et al 28 also reported BU PK parameters in a small number (n ϭ 14) of children, including seven with Hurler syndrome; however, data in children with Hurler syndrome were not reported separately. To date, no study has adequately addressed the contribution of BU PK and marrow nucleated cell dose to donor-derived engraftment in IMSD children receiving HCT.
We found that oral BU Cl/F in IMSD children were comparable to that reported for other age matched children (Table 6 ). Our data confirmed that children р3 years of age had a higher Cl/F, lower AUC and Cp than older children with IMSD. Hurler children had a higher Cl/F, lower AUC and Cp than other IMSD children, althrough the differences were not significant (P у 0.06). Therefore, BU PK differences in Hurler children would appear to be attributable to normal age-dependent clearance rather than to higher metabolic capacity intrinsic to Hurler syndrome.
BU PK parameters differed between dose four and eight; clearance increased while AUC and Cp decreased. We hypothesize that these changes could stem from the ability of BU to induce its own metabolism or the induction of BU metabolism by phenytoin. 15, 29 In our study, we analyzed BU PK from BU dose four, which are likely to be the most clinically relevant. If BU dose adjustments were to occur, they would be based on PK data derived from an early dose of BU.
Achieving permanent donor-derived engraftment has been problematic in Hurler patients. Related and unrelated donor HCT for Hurler syndrome have resulted in donorderived engraftment in only 63-85% of patients while engraftment rates are у85% in patients with malignant disease and other IMSD such as adrenoleukodystrophy. 7, 8 Low rates of donor chimerism have been attributed to various factors including insufficient myeloablation due to subopti-859 Table 6 Busulfan clearance in pediatric patients with respect to age mal chemotherapy exposure, inadequate immunosuppression, and/or, in the case of Hurler syndrome, abnormal heparan sulfates in the marrow microenvironment. Therefore, the primary objectives of this study were to determine if BU PK were different in Hurler syndrome vs other IMSD and in patients not achieving donor-derived engraftment.
We did not observe a significant association between BU PK parameters and early donor-derived engraftment. Previous reports demonstrated a good relationship between BU exposure and engraftment in 38 pediatric and adult allogeneic patients who received BU (16 doses) with CY (total dose range, 120-200 mg/kg), and various GVHD prophylaxis regimens. 15 A BU Cp of least 600 ng/ml was necessary in the HLA partially matched or matched unrelated donor recipient to prevent graft rejection. In 31 children treated with conventionally dosed BU/CY undergoing allogeneic related and unrelated HCT who were targeted to achieve BU Cp between 600 and 900 ng/ml, a higher rate of autologous recovery and mixed chimerism was found in children with a BU Cp Ͻ600 ng/ml. 30 In contrast, Pawlowska et al 31 did not find a significant association between BU exposure and engraftment in 64 children and young adults undergoing HLA-identical sibling donor HCT conditioned with BU/CY for thalassemia. Varying total doses of CY (120-200 mg/kg) and GVHD prophylaxis regimens were used. The rate of graft rejection was low (ie 7.5%). Six patients had a low BU Cp (ie Ͻ200 ng/ml), but despite this all engrafted. Higher rates of graft rejection were noted in children who received lower total doses of CY (120 mg/kg vs 200 mg/kg, P ϭ 0.02). Regazzi et al 11 described BU exposure and engraftment in a small series of 13 patients who received allogeneic HCT for lymphohematopoietic malignancies, immunodeficiency disorders, and thalassemia. Although engraftment data were not analyzed, the rate was high (ie 92%); a child with a BU Cp Ͻ200 ng/ml rejected the graft.
Overall, there was no difference in BU Cp in our patients with early full or partial engraftment vs those without. This was also true in a subanalysis of children with Hurler syndrome. We believe that poor early donor-derived engraftment in our study may be attributable to other factors, such as suboptimal immunosuppression, the use of single fraction TBI and T cell depletion, predominance of unrelated donors, an abnormal Hurler marrow microenvironment, the unrecognized effects of the CY dose and/or a lower total busulfan exposure (eight doses). However, the latter is unlikely since Hurler children undergoing unrelated donor transplant who receive conventional dose BU (16 doses) with CY have an engraftment failure rate of 44%. 7 T cell depletion, particularly in the unrelated donor setting, is associated with lower rates of donor engraftment and may have overriding effects on chemotherapy exposure. Other factors such as the use of TBI and post-transplant immunosuppressive regimens also have significant roles in establishing engraftment. Previous studies have characterized heparan sulfates in the marrow that are optimally supportive of normal hematopoietic progenitors such as LTC-IC in vitro. 32, 33 We speculate that engraftment of normal hematopoietic progenitors may be diminished as a result of an abnormal Hurler marrow microenvironment. It is also plausible that the CY dose is an important variable. In the previously cited thalassemia trial, higher rates of graft rejection were observed in children treated with CY 120 mg/kg vs 200 mg/kg. 31 Late graft failure was a problem. Overall, late full or partial engraftment was present in 78% of evaluable children. There appeared to be a subset of children who, despite robust early donor-derived engraftment gradually lost donor chimerism over a number of months with recovery of normal recipient hematopoiesis. No cases of complete aplasia were observed. We did not evaluate the relationship between BU PK and late engraftment due to the small number of patients. However, we believe that it is unlikely that BU exposure is related to late engraftment failure. Busulfan is primarily myeloablative and has few immunosuppressive effects; therefore, its role is most likely in establishing early engraftment. Late engraftment failures may be related to an abnormal marrow environment, inadequate immunosuppression and/or low hematopoietic cell dose.
The incidence of VOD following a conventional BU/CY conditioning regimen is р30%. [34] [35] [36] [37] [38] [39] In our study the overall incidence of VOD was low (ie 8%). This may have been due, in part, to the lower total dose of BU, lack of prior chemotherapy and/or the young age of our patients. Since all patients developing VOD had a CpϾ1000 ng/ml and died, BU PK monitoring and targeting may be indicated to ensure safety.
Important questions related to BU and IMSD remain. First, what is the contribution of the route of administration (ie oral vs intravenous) to engraftment? To date, no data have been reported evaluating intravenous BU in children with IMSD or the relationship between intravenous BU PK parameters and engraftment and toxicity. Second, should less intensive conditioning regimens be utilized for patients with IMSD including Hurler syndrome with significantly compromised cardiac and/or pulmonary function? A substantial proportion of patients present to transplantation with compromised organ function and enhancing the intensity of the preparative regimen to promote engraftment may not result in better overall survival. There is emerging interest in using safer, less intensive HCT conditioning regimens to obtain a mixed donor chimerism that would adequately produce the absent enzyme. Carefully performed pilot clinical studies of such regimens for IMSD patients may shed light on these questions.
In summary, BU PK did not differ in Hurler children compared with other IMSD children. Nucleated cell dose did not correlate with donor-derived engraftment. Therefore, BU exposure in the HCT preparative regimen did not explain the observed differences in the rates of donorderived engraftment. BU disposition did not differ from reported data in children with malignant or marrow failure syndromes of comparable age. Further study is needed to ascertain whether the low rates of donor-derived engraftment following both related and unrelated donor HCT in Hurler syndrome can be attributed to other factors such as the degree of myeloablation and immunosuppression or characteristics of the Hurler marrow microenvironment. Significant progress in the treatment of Hurler syndrome as well as IMSD will be accomplished most effectively through careful analysis of complete data, worldwide implementation of the highest standards of care, and thoughtful planning of clinical trials.
